Using high‐resolution array tomography to validate the use of synaptic vesicle glycoprotein 2A as a biomarker for synaptic loss in Alzheimer's disease

These data indicate that changes in SV2A signal observed in AD with PET imaging likely reflect changes in synapse density rather than changes in protein levels within remaining synapses. Future work with the Foundations for the National Institutes of Health SV2A project team will integrate these data with in vivo PET imaging and molecular analyses of post-mortem tissue to provide further understanding of the biological underpinnings of SV2A PET signal with the goal of determining whether SV2A PET will be a reliable marker of synapse density for use in future clinical use.